Gelre Hospitals

Running trials

• Not yet recruiting

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· Phase 2· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Source

• Recruiting

  Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

  NCT06161818· Phase 2· Source

• Not yet recruiting

  A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC

  2025-520792-67-00· Phase 3· Source

• Recruiting

  StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial

  2024-517343-31-00· Phase 4· Source

• Recruiting

  A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.

  NCT02371304· Phase 3· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Source

• Recruiting

  DAROTAXEL

  2024-516939-28-00· Phase 2· Source

• Recruiting

  Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

  NCT06220032· Phase 3· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Source

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Source

• Recruiting

  Induction Chemotherapy for Locally Recurrent Rectal Cancer

  NCT04389086· Phase 3· Source

• Active, not recruiting

  The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

  NCT03463057· Phase 2· Source

• Active, not recruiting

  Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.

  NCT03348150· Phase 3· Source

• Recruiting

  DRUP trial

  NCT02925234· Phase 2· Source

• Active, not recruiting

  Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

  NCT01898117· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke4 recruiting
• Atrial fibrillation2 recruiting
• Colorectal cancer2 recruiting
• Multiple myeloma2 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

  NCT05254002· Phase 2· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Source